SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
ZMT
Lv1
1
40 积分
2023-08-29 加入
最近求助
最近应助
互助留言
The potential of CD38 protein as a target for autoimmune diseases
2小时前
已完结
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
10天前
已完结
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
12天前
已完结
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
1个月前
已完结
Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy
3个月前
已完结
A new alternative: inhibiting complement activation in patients with IgA nephropathy
3个月前
已完结
Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy
3个月前
已完结
A new alternative: inhibiting complement activation in patients with IgA nephropathy
3个月前
已完结
Revisiting the hERG safety margin after 20 years of routine hERG screening
3个月前
已完结
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
4个月前
已完结
没有进行任何应助
收到感谢
9个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论